(COG ALTE1621) Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
To determine the impact of a two-year course of low-dose carvedilol on surrogate echocardiographic indices of heart failure (HF) risk, including:Left Ventricular (LV) Posterior Wall Thickness-Dimension Ratio (LV T-D) a well-established index of early myocardial remodeling and subsequent HF risk (primary endpoint). LV systolic and diastolic function, and afterload established echocardiographic indices associated with HF risk. Natriuretic peptides, troponins, and Galectin-3 - circulating biomarkers associated with myocardial injury, and HF risk.
Study Number: 

NCG 287516

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.